---
document_datetime: 2023-09-21 18:48:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pioglitazone-krka-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: pioglitazone-krka-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.01678
conversion_datetime: 2025-12-30 22:01:58.355716
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended no   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------------------------|-----------|
| IB/0001              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal | on 12/11/2013 product                                                         | SmPC, Annex II, Labelling and PL |           |

<!-- image -->

<!-- image -->